Skip to Main Content

Meet Dr. Harriet Kluger

September 10, 2021

Harriet Kluger, MD, discusses her care of patients with melanoma and renal cell cancers, and recent treatment advances.

ID
6900

Transcript

  • 00:00I'm Harriet kluger. I'm a professor
  • 00:02of medicine in medical oncology.
  • 00:04I treat patients with Melanoma and
  • 00:06renal cell carcinoma as well as
  • 00:08patients with other types of skin
  • 00:10cancers such as Merkel cell carcinoma.
  • 00:12Towards the end of the 1990s it was
  • 00:15becoming clearer and clearer that the
  • 00:17big breakthroughs in understanding
  • 00:19cellular biology would have major
  • 00:20impact on oncology and therefore
  • 00:22I decided to go into this field
  • 00:24where I felt that I could actually
  • 00:26make a difference in contributing
  • 00:29not only to patient care but in.
  • 00:31To moving the field forward
  • 00:33by doing clinical research,
  • 00:34I generally recommend that people come
  • 00:36into their first visit with a family
  • 00:39member or a caregiver simply because
  • 00:41the first visit is very overwhelming.
  • 00:43We give people a lot of information and
  • 00:46I think it's hard to retain all of it.
  • 00:49So second set of ears is always beneficial.
  • 00:52When I started taking care
  • 00:53of patients with cancer,
  • 00:55we pretty much only had chemotherapy
  • 00:57as the molecular abnormalities
  • 00:58within the cancer cells became
  • 01:00better and better understood.
  • 01:01We were able to develop drugs that target
  • 01:04those political molecular abnormalities.
  • 01:06So, in Melanoma,
  • 01:07the molecular lesions are mutations in a gene
  • 01:09called byref primarily and in kidney cancer.
  • 01:12We we have developed a whole slew of
  • 01:14drugs that target the blood cell for the
  • 01:17blood vessel formation within the tumor.
  • 01:19So essentially,
  • 01:20when we inhibit that,
  • 01:22we starve the tumor a little
  • 01:24bit of its nutrients,
  • 01:25and that's very effective in kidney cancer.
  • 01:27The other major approach,
  • 01:29and that's where most of the
  • 01:31breakthroughs have actually occurred.
  • 01:33Is in immunotherapy for cancer,
  • 01:34so these cells sit within
  • 01:36a tumor microenvironment.
  • 01:37They're not just sitting there by themselves,
  • 01:40and if we can educate the immune system
  • 01:42to recognize the cancer's foreign
  • 01:44and then activate it a little bit
  • 01:46further to attack those cancer cells,
  • 01:49we can then essentially get rid of the
  • 01:51cancer using our own bodies immune
  • 01:53system as the ammunition to do so.
  • 01:56We have two fantastic teams that
  • 01:58we work with,
  • 01:59one for skin cancer and one
  • 02:01for kidney cancer.
  • 02:02We're fortunate to have dedicated surgeons.
  • 02:04Who understand the biology of the disease.
  • 02:07They understand the drugs
  • 02:08that they use that we use.
  • 02:11They meet with us on a weekly basis
  • 02:13and are able to tailor specific
  • 02:16treatment plans for individual patients.